SANJAY DESHPANDE to Recurrence
This is a "connection" page, showing publications SANJAY DESHPANDE has written about Recurrence.
Connection Strength
0.065
-
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. Cancer Med. 2022 01; 11(1):61-73.
Score: 0.036
-
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018 08 10; 36(23):2405-2412.
Score: 0.029